Chemodex

Linezolid

CHF 162.00
In stock
CDX-L0031-M02525 mgCHF 162.00
More Information
Product Details
Synonyms N-[[(5S)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide; PNU-100766; U-100766
Product Type Chemical
Properties
Formula C16H20FN3O4
MW 337.35
CAS 165800-03-3
RTECS AC2720000
Source/Host Chemicals Synthetic
Purity Chemicals ≥98% (HPLC)
Appearance White to off-white powder.
Solubility Soluble in DMSO (20mg/ml), DMF or chloroform. Slightly soluble in ethanol (1mg/ml) methanol. Insoluble in water.
Identity Determined by 1H-NMR.
Declaration Manufactured by Chemodex.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

InChi Key TYZROVQLWOKYKF-ZDUSSCGKSA-N
Smiles CC(NC[C@H]1CN(C2=CC=C(N3CCOCC3)C(F)=C2)C(O1)=O)=O
Shipping and Handling
Shipping AMBIENT
Short Term Storage -20°C
Long Term Storage -20°C
Handling Advice Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Description

Linezolid is a synthetic oxazolidinone antibiotic with activity against a wide range of Gram-positive bacteria. Displays potent antibacterial activity against a variety of multidrug-resistant gram-positive microbes in vitro and in vivo, including resistant strains of several species, such as methicillin-resistant S. aureus (MRSA), penicillin-resistant pneumococci, vancomycin-resistant enterococci, various anaerobic bacteria, and several mycobacteria and streptococci (MICs = 2-4mg/ml). Linezolid inhibits protein synthesis by binding to domain V of the 23S ribosomal RNA of the 50S subunit of bacterial ribosomes and preventing the formation of a functional 70S initiation complex, thus inhibiting bacterial mRNA translation. Linezolid is also a weak, reversible, nonselective inhibitor of monoamine oxidase.

Product References

(1) C.W. Ford, et al.; Antimicrob. Agents Chemother. 40, 1508 (1996) | (2) S.J. Brickner, et al.; J. Med. Chem. 39, 673 (1996) | (3) R.N. Jones, et al.; Antimicrob. Agents Chemother. 40, 720 (1996) | (4) D. Clemett & A. Markham; Drugs 59, 815 (2000) (Review) | (5) H.B. Fung, et al.; Clin. Ther. 23, 356 (2001) (Review) | (6) C.W. Ford, et al.; Curr. Drug Targets Infect. Disord. 1, 181 (2001) (Review) | (7) D.M. Livermore; J. Antimicrob. Chemother. 51, ii9 (2003) (Review) | (8) S.J. Brickner, et al.; J. Med. Chem. 51, 1981 (2008) (Review) | (9) K.L. Leach, et al.; Ann. N. Y. Acad. Sci. 1222, 49 (2011) (Review) | (10) S. Ager & K. Gould; Infect. Drug Resist. 5, 87 (2012) | (11) B.A. Diep, et al.; Curr. Ther. Res. Clin. Exp. 73, 86 (2012) (Review) | (12) L.A. Pauchard, et al.; PLoS One 12, e0187187 (2017)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.